3 High-Yield Dividend Stocks to Buy Hand Over Fist in June

The article highlights three high-yield dividend stocks—AbbVie, Chevron, and Enterprise Products Partners—citing yields of over 3.0%, 3.8%, and 5.8%, respectively, along with long records of dividend growth and buybacks. AbbVie’s 54-year dividend-hike streak, Chevron’s ability to fund dividends even below $50 oil, and Enterprise’s 27 straight years of distribution increases are presented as key income-investing positives. The piece is broadly constructive on defensive income stocks but is primarily opinion-driven commentary rather than new company-specific news.

Analysis

This is less a generic “yield trade” and more a barbell on scarce cash-flow durability at a time when discount rates may stay higher for longer. In that regime, the market tends to pay up for visible capital return streams while punishing anything with refinancing risk or weak payout coverage, so the relative winners are the names with either fortress balance sheets or self-funding distributions. ABBV and CVX fit the former, EPD the latter; the common thread is that each can sustain distributions without needing a favorable financing window.

The second-order effect is that a sticky-rate backdrop actually improves the earnings quality premium for these names versus bond proxies and lower-quality dividend traps. ABBV’s multiple can keep rerating if pipeline optionality is perceived as de-risked, but the more interesting torque may be in EPD: inflation-linked contracts plus energy infrastructure demand from AI/data-center power load creates a duration asset inside a value wrapper. CVX is the cleanest hedge against an inflation surprise, but the real asymmetry is that buybacks can accelerate per-share compounding even if commodity prices merely stay range-bound.

The main risk is consensus complacency around payout safety. For ABBV, the market is implicitly assuming seamless post-Humira offset and pipeline conversion; any clinical slip would hit both growth and yield-supporting sentiment within 1-2 quarters. For CVX/EPD, the bear case is not oil collapsing so much as spreads normalizing and midstream volumes underwhelming if global growth rolls over; that would compress the “high yield plus growth” narrative even if the distributions remain intact.

Contrarian view: the market may be overestimating the urgency to own income simply because cuts are delayed. If inflation stays hot, the long-duration equity factor remains vulnerable, but the highest-quality cash returners should still outperform mediocre bond substitutes. The better trade is not “buy all dividends,” it is “buy self-funded capital return with pricing power” and avoid names whose yield is only high because the stock is cheap for structural reasons.

Key Decisions for Investors

• Go long ABBV vs. a basket of lower-quality high-yield healthcare dividend names over 3-6 months; use any post-data pullback to add, targeting a mid-single-digit total return plus defensive downside capture.
• Initiate a long CVX / short XLE pair for 2-4 months; CVX’s buyback support and payout resilience should outperform the broader energy basket if crude stays range-bound rather than exploding higher.
• Buy EPD on weakness for a 12-month hold; the setup is attractive for income with limited fundamental downside, and the risk/reward favors collecting yield while waiting for AI-linked midstream volume growth to show up.
• If rates spike again, rotate away from REITs/utilities into ABBV-CVX-EPD as a “cash-flow duration” basket; this should outperform traditional yield sectors by 300-500 bps in a risk-off, higher-for-longer tape.
• Avoid chasing names with yield but no growth visibility; the best risk-adjusted income here is in companies that can grow distributions from internal cash flow rather than financial engineering.